


Thrombocytopenia up with use of phosphate-buffered tirofiban

August 16 2016



(HealthDay)—For patients with acute coronary syndrome, phosphate-

buffered tirofiban, but not citrate-buffered tirofiban, is associated with an increased risk of thrombocytopenia, according to a study published in the Aug. 22 issue of *JACC: Cardiovascular Interventions*.

Marianna Adamo, M.D., from Erasmus Medical Center in Rotterdam, Netherlands, and colleagues randomized 3,232 patients to receive tirofiban or unfractionated heparin (UFH). A total of 879 patients were allocated to phosphate-buffered tirofiban and 874 to the UFH group in the early phase, and 737 and 742 patients were treated with citrate-buffered tirofiban and UFH, respectively, in the late phase.

The researchers found that patients treated with phosphate-buffered tirofiban had an increased relative risk for thrombocytopenia in the early phase (odds ratio, 3.51 [95 percent confidence interval (CI), 1.15 to 10.73] for nadir

Citation: Thrombocytopenia up with use of phosphate-buffered tirofiban (2016, August 16)
retrieved 26 April 2024 from

<https://medicalxpress.com/news/2016-08-thrombocytopenia-phosphate-buffered-tirofiban.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--